Treatment patterns and survival outcomes in patients with non-metastatic early-onset pancreatic cancer

Table 1 Clinical characteristics in patients with non-metastatic early-onset pancreatic cancer

Characteristics	n (%)
Age (yr)
Median (range)	46 (20-50)
< 45	115 (41.5)
≥ 45	162 (58.5)
Sex
Male	190 (68.6)
Female	87 (31.4)
Tumor site
Body and tail	85 (30.6)
Head	193 (69.4)
Clinical manifestation
Abdominal pain	136 (49.1)
Jaundice	83 (30.0)
New-onset diabetes	12 (4.3)
Back pain	9 (3.2)
No symptoms	28 (10.1)
Others	9 (3.2)
History of tobacco	102 (36.8)
History of alcohol	72 (26.0)
Obesity	19 (6.9)
Pre-existing diabetes	10 (3.6)
History of chronic pancreatitis	6 (2.2)
Baseline CA19-9 (U/mL)
≥ 150	126 (51.2)
< 150	120 (48.8)
Unknown	31
Pathological grade
Well	12 (5.4)
Moderate	110 (49.5)
Poor	100 (45.0)
Unknown	55
T-stage
1	33 (11.9)
2	124 (44.8)
3	56 (20.2)
4	62 (22.4)
X	2 (0.7)
N-stage
0	172 (62.1)
1	95 (34.3)
2	10 (3.6)
Clinical stage
Localized	215 (77.6)
Locally advanced	62 (22.4)
Resection	218 (78.7)
Chemotherapy	207 (74.7)
Radiotherapy	75 (27.1)
Immunotherapy	86 (31.0)
Targeted therapy	55 (19.9)

CA19-9: Carbohydrate antigen 19-9; X: No assessment.